Crescent Biopharma, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CBIO Nasdaq 2836 crescentbiopharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Crescent Biopharma, Inc.

Crescent Biopharma Announces Grants of Inducement Awards - May 29th, 2026 2:15 pm
Crescent Biopharma to Present at May Investor Conferences - May 6th, 2026 5:30 am
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights - Apr 29th, 2026 2:15 pm
Crescent Biopharma: Q4 Earnings Snapshot - Feb 26th, 2026 6:05 am
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - Feb 26th, 2026 5:30 am
Crescent Biopharma to Present at March Investor Conferences - Feb 23rd, 2026 5:30 am
Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors - Feb 18th, 2026 5:30 am
Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - Feb 5th, 2026 5:30 am
Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA - Jan 5th, 2026 5:00 am
Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors - Jan 5th, 2026 5:00 am
Huge Insider Buying in MGM and Salesforce - Dec 12th, 2025 7:45 am
Crescent and Kelun-Biotech swap cancer asset rights in double deal - Dec 5th, 2025 7:36 am
Praxis soars higher; Bristol Myers’ CAR-T therapy wins broader use - Dec 5th, 2025 3:00 am
Crescent Biopharma, Kelun-Biotech Biopharmaceutical Partner in Multimillion Dollar Deal to Develop Cancer Drugs - Dec 4th, 2025 5:13 am
Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors - Dec 4th, 2025 4:35 am
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics - Dec 4th, 2025 4:30 am
Sickle Cell Disease Treatment Market Research Report 2025 Featuring Novartis, Pfizer, Bluebird Bio, GlycoMimetics, Emmaus Medical, BMS, CRISPR Therapeutics, Graphite Bio - Nov 11th, 2025 7:40 am
Crescent Biopharma: Q3 Earnings Snapshot - Nov 6th, 2025 5:40 am
Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights - Nov 6th, 2025 5:30 am
Crescent Biopharma to Present at November Investor Conferences - Nov 5th, 2025 5:30 am